Lucid Diagnostics Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-58.0M | $-45.5M | $-52.7M | $-56.2M | $-28.1M | $-8.3M |
| Depreciation & Amortization | $872.0K | $1.2M | $2.5M | $1.9M | $4.0K | — |
| Depreciation | $451.0K | $479.0K | — | — | $4.0K | — |
| Amortization | $421.0K | $688.0K | $2.0M | $1.6M | $0 | — |
| Stock-Based Compensation | — | $4.2M | $5.8M | $13.9M | $9.1M | $65.0K |
| Net Cash from Operating Activities | $-46.5M | $-44.1M | $-32.8M | $-29.7M | $-17.7M | $-5.6M |
| Investing Activities | ||||||
| Capital Expenditures | $197.0K | $296.0K | — | $3.2M | $862.0K | — |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-197.0K | $-646.0K | $-221.0K | $-4.1M | $-862.0K | — |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $59.0M | $48.2M | $29.5M | $2.6M | $72.1M | $5.6M |
| Net Change in Cash | $12.3M | $3.5M | $-3.6M | $-31.2M | $53.5M | $-45.0K |
| Free Cash Flow | $-46.7M | $-44.4M | — | $-32.9M | $-18.5M | — |